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Abstract
Background: Iron deficiency anemia (IDA) is highly prevalent in women of child-bearing age. However, their
nonhematological symptoms have been overlooked. This study aims to analyze the nonhematological features
and symptoms of IDA in a group of women of reproductive age and the changes occurred during iron therapy.
Materials and Methods: IDA women underwent dietary, physical activity, menstrual blood loss, and cognitive
function assessment at baseline. Hematological and biochemical parameters were analyzed. Executive attention
was tested by the flanker task and working memory by the 2-back task. Oral iron therapy (ferrous sulfate) was
given to 35 women for 8 weeks and the changes in iron status, biochemical markers, cognitive function, and
nonhematological symptoms were evaluated.
Results: Patients presented nonhematological symptoms: pica, 32.4%; cheilitis, 20.6%; restless legs syndrome
(RLS), 20.6%; diffuse hair loss, 55.9%; and ungual alterations, 38.2%. Two or more symptoms were present in
58.8% of women. Serum iron and working memory were correlated at baseline. Multivariate analyses show as-
sociations (odds ratio [OR], 95% confidence interval [CI]) between pica and reaction time in the working memory
test (OR 2.14, 95% CI 1.19–3.87, p = 0.012); RLS with total serum protein (OR 0.08, 95% CI 0.06–0.92, p = 0.043); and
cheilitis with mean corpuscular hemoglobin (OR 0.388, 95% CI 0.189–0.799, p = 0.01). Pica, cheilitis, and RLS com-
pletely resolved with iron therapy, and ungual alterations and hair loss improved in 92.3% and 84.2% of women,
respectively. Better performance in executive attention and working memory was observed after iron therapy.
Conclusions: More attention should be given to the nonhematological manifestations of IDA to improve the
quality of life of menstruating women.
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Introduction
Iron deficiency (ID) is the most common nutritional
deficiency in the world and is the leading cause of ane-
mia in both developed and developing countries. The
greatest prevalence of iron deficiency anemia (IDA) is
found in women of reproductive age and preschool
children, regardless of geographic region or economic
status.1
ID occurs as a spectrum beginning with tissue iron
store depletion and progressing to impaired eryth-
ropoiesis and anemia. Iron is an essential element re-
quired for numerous vital processes, including energy
metabolism, cell signaling, gene expression, and cell
growth regulation and differentiation.2 These functions
are so basic that ID has far reaching consequences on
systemic functions apart from the well-known feature
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of anemia, but the nonhematological symptoms of this
trace element deficiency have been often overlooked.
Nonhematological manifestations of ID include fa-
tigue, reduced physical endurance, defective structure
or function of epithelial tissues, pica, restless legs syn-
drome (RLS), decreased cognitive performance, and
behavioral disturbances.3,4 ID impairs the health and
well-being of women and increases the risk of ad-
verse maternal and neonatal outcomes.5,6 Our research
group has observed elevated bone remodeling in IDA
young adult women that improved during iron recovery,
suggesting that chronic ID may be a risk factor for future
osteoporosis in women.7–9 According to the Global Bur-
den of Disease Study 2016, IDA is the first cause of years
lived with disability burden in women.10 Nevertheless,
there remains a lack of awareness of the clinical conse-
quences of IDA among this population.
The aim of this study was to prospectively analyze
the characteristics, analytical data, and nonhematolog-
ical signs and symptoms of IDA in a homogeneous




Participants were required to be Caucasian women aged
between 18 and 40 years with IDA. Patients were in-
cluded when they had hemoglobin £110 g/L, mean cor-
puscular volume <98 fL, transferrin saturation <15%
and ferritin <20 ng/mL, or if ferritin was 20–50 ng/mL,
soluble transferrin receptor (sTfR) was >5 mg/L.
Exclusion criteria were as follows: smoking, amen-
orrhea, menopause, current pregnancy or pregnancy
within the previous year, breastfeeding, thalassemia,
iron metabolism-related diseases such as hemochroma-
tosis, bleeding disorders, autoimmune diseases, chronic
gastrointestinal diseases (inflammatory bowel disease,
gastric ulcers, coeliac disease, and Crohn’s disease),
neoplastic diseases, renal disease or hormone-related
diseases independent of IDA, chronic inflammation
(C-reactive protein >5 mg/L), creatinine levels >1.0 mg/
dL (120 lmol/L), abnormal liver tests (>2 times nor-
mal), blood donation in the past 3 months, current
use of iron supplements, and excess alcohol consump-
tion or use of recreational drugs, prescription drugs, or
herbal preparations that could interfere with iron ab-
sorption and/or affect mental performance.
Over 18 months, 84 women who met the inclusion
criteria were interviewed by telephone to assess all
exclusion criteria. After the exclusion criteria were ap-
plied, 36 women agreed to participate: 1 subject aban-
doned the study due to a change of residence.
Study protocol
This prospective interventional study was conducted at
the Complejo Hospitalario de Toledo, Spain, in 2014, as
a part of a larger long-term project. The study followed
guidelines stated in the Declaration of Helsinki and was
approved by the Complejo Hospitalario de Toledo Clin-
ical Research Ethics Committee and the Spanish National
Research Council Ethics Committee (Bioethics subcom-
mittee). Written informed consent was obtained from
all participants before study commencement.
At enrolment, a full medical history was recorded,
and anthropometric measurements were carried out.
Patients underwent dietary, physical activity, menstrual
blood loss, and cognitive function assessment. Blood
samples were taken for complete blood count (CBC),
coagulation tests, and measures of iron status and
other biochemical parameters.
Patients were prescribed 8 weeks of oral iron ther-
apy in the form of ferrous sulfate tablets (Tardyferon;
Pierre Fabre Médicament, Boulogne, France): one tab-
let (80 mg Fe) daily if hemoglobin >100 g/L, or two
tablets a day (160 mg Fe) if hemoglobin <100 g/L.
Patients were instructed to take the tablets in fasting
conditions with water or orange juice. At the time the
study was conducted, this was the conventional treat-
ment for ID, but mounting evidence indicates that
low doses and treatment on alternate days are more
effective and better tolerated.11–13
A follow-up visit was scheduled 9 weeks after the
baseline visit, 1 week after completing the prescribed
pharmacological treatment to allow iron levels to stabi-
lize. Blood samples were taken to repeat the CBC and
biochemical parameters measurement and cognitive
function was assessed again. Patients were asked to re-
port possible side effects associated with the treatment
and any health problems from their last visit. If patients
had not recovered from anemia and/or ID after the first
8-week cycle of treatment (hemoglobin >120 g/L and
ferritin ‡15 ng/mL), a further 8 weeks of treatment
was prescribed, with a second follow-up visit scheduled
1 week after finishing the second cycle of treatment.
Figure 1 shows the study flow chart.
Complete response was defined by normalization of
Hb (Hb >120 g/L) and serum ferritin ‡15 ng/mL, the
ferritin cutoff value suggested by the World Health
Organization to indicate depleted iron stores for individ-
uals of 5 years of age or older.14 A final Hb >120 g/L but
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serum ferritin <15 lg/L, or an increase in Hb ‡20 g/L
were regarded as incomplete response.
The compliance of the study was assessed by ques-
tionnaires and a personal interview in each visit. Patients
were asked about the number of tablets that were taken
throughout treatment.
Data collection
Clinical data. Medical history was taken by an hema-
tologist at the time of initial evaluation through a pre-
structured questionnaire that included medication,
dietary supplements, any past or present prestructured
questionnaire medical conditions, previous opera-
tions, and reproductive history. Particular attention
was given to a family history of anemia, hypercholes-
terolemia, hypertension, osteoporosis, and kidney or
thyroid disease. Patients were questioned specifically
about whether they had pica or other symptoms attrib-
uted to ID, such as fatigue, epithelial manifestations
(hair loss, angular cheilitis, and brittle nails), and neu-
romuscular symptoms (RLS). Pica was defined as the
compulsive eating of food or nonfood items, singly or
in combination, not part of the patient’s habitual diet
or preferences.
Menstrual cycle duration, period length, and num-
ber of days with intense menstrual blood loss (heavy
bleeding days) were monitored using a self-administered
paper questionnaire, as described previously.15,16 Ques-
tions on the presence of blood clots, bleeding lasting
>7 days, and whether multiple pads or tampons were
saturated during the menstrual flow period were also
included. Patients with heavy blood loss were voluntar-
ily referred to a gynecologist for further evaluation. The
use of oral contraceptives was also recorded.
A short questionnaire was used to assess overall
physical activity. Questions included duration and in-
tensity of daily walking and moderate- and vigorous-
intensity activities per week.17
FIG. 1. Flow chart.
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Anthropometric data. Height and weight were
obtained at baseline and weight measurements were
repeated on next visit/s. Weight was measured to the
nearest 100 g using a medical weighing scale (Seca Ltd,
Hamburg, Germany) and height was measured with a
stadiometer incorporated into the scale. Body mass
index (BMI) was worked out via the formula: weight
(kg)/height (m2).
Hematological and biochemical assays
Blood samples were collected between 8:00 and 10:00 by
venepuncture after a 12-hour fasting period. Serum and
plasma were obtained after centrifugation (for 5 minutes
at 1000 g). The CBC was measured in whole blood fol-
lowing standard laboratory techniques using the Beck-
man Coulter LH780 Analyzer (Beckman Coulter, Brea,
CA). Routine coagulation tests including prothrombin
time, activated partial thromboplastin time, and fibrin-
ogen were assayed on a blood coagulation analyzer ACL
TOP 700 (Beckman Coulter). Serum iron, serum ferri-
tin, total iron binding capacity, serum vitamin B12,
serum folate, sTfR, and other biochemical variables
were determined by modular analyzers (Elecsys and
Modular DP; Roche Diagnostics, Mannheim, Germany).
Dietary assessment
Each subject’s dietary intake was evaluated at baseline
with a 72-hour detailed dietary intake report, previ-
ously validated and proved valuable to assess nutrient
intake18 specifying the types of food consumed and
serving weights. The possible food intake changes
throughout the study were monitored using a food
frequency questionnaire. The options of frequency of
consumption and their corresponding codes were as
follows: never (0), less than once a week (0.5), once a
week (1), two to three times a week, four to six times
a week (2.5), daily (7), and more than once a day (10).
Cognitive testing
Cognitive performance was assessed at baseline and
follow-up. Two cognitive tasks were included in this
study: Verbal version of the flanker task19 that tests ex-
ecutive attention and 2-back task20 that is widely used
to measure working memory. The computerized pro-
grams of both tasks were taken from the COG-LAB-
UAM Battery.21 Verbal flanker task required deciding,
as fast as possible, whether the letter in the center of a
set of three letters was vowel or consonant. The target
(e.g., vowel) could be surrounded by compatible (e.g.,
vowel) or incompatible letters (e.g., consonant). There
were a total of 22 practice trials and 80 test trials. Half
of the trials were compatible, and they were randomly
presented across the session. Mean reaction time for
correct responses and number of hits and errors were
recorded. Given that speed–accuracy trade-off could
vary between experiments, participants, and conditions,
we used the inverse efficiency score (IES),22 which
adjusts the reaction time by the proportion of correct
answers, combining speed and accuracy into a single
measure. High IES values indicate a less efficient perfor-
mance, that is, greater difficulties in solving the task. In
the 2-back task, upper and lower case letters were pre-
sented in one of eight equidistant spatial locations
around the center of the screen. Stimuli were presented
for 200 ms and 1300 ms were given for responding.
There were 75 test stimuli of which 24 were match stim-
uli. Participants pressed the space bar of the keyboard to
make a match response (a letter presented in the same
spatial location two positions back in the sequence).
To assess potential confounding variables, subjects
filled out a short questionnaire aimed to determine pa-
tients’ latest education level, profession, urban–rural
residence, and level of interaction with computers,
before completing the computerized cognitive tests.
All sessions were monitored by trained research staff,
overhead lighting was kept low, the subject was asked
to maintain a fixed distance from the screen, and envi-
ronmental distractions were minimized.
Statistical analysis
The collected data were analyzed using the SPSS for
Windows program (version 25.0; IBM Corp., Armonk,
NY). All continuous variables were analyzed for nor-
mality and, when required, were log-transformed to
achieve normality. Pearson correlation coefficient was
used to analyze correlations between continuous vari-
ables. A stepwise-forward multiple linear regression
analysis was used to determine which variables con-
tribute significantly to the results of cognitive tests.
To identify factors associated with nonhematological
symptomatology, univariate and multivariate logistic
regression analyses were applied. Pretreatment and
post-treatment cognitive assessments were compared
using paired t-tests. The level of statistical significance
was considered as p < 0.05.
Results
Patient characteristics and evaluation
A total of 35 anemic young women completed the
study. In total, 74.3% of participants reported past
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personal history of IDA and 57.1% had female family
history of IDA (first- and/or second-grade relatives).
Patient characteristics and hematological data at base-
line are summarized in Table 1.
Most participants (85.3%) reported IDA-related non-
hematological symptomatology: 32.4% pica (ice or
one particular food, especially crunchy foods), 20.6%
cheilitis, 20.6% RLS, 55.9% diffuse hair loss, 38.2% un-
gual changes, and 20.6% intense fatigue. Four patients
reported headache, one tinnitus and another one dys-
phagia (without esophageal webs). In total, 58.8% of
women had two or more symptoms associated with IDA.
Heavy menstrual bleeding according to the ques-
tionnaire was reported by 24 patients (68.6%), 9 out
of them presented some physical condition affecting
the uterus, such as fibroids and polyps, after further
evaluation. Seven women refused gynecological exam-
ination. All patients showed normal coagulation tests.
Only four women used oral contraceptives.
No significant differences were found in nutrient
intake between patients nor in women’s diet among base-
line and end of treatment, except for ‘‘fruit juices at
breakfast’’ that showed an increased consumption (me-
dian increased from never to once a week) ( p = 0.015)
and ‘‘other dairy products at breakfast’’ that decreased
(median values lower than once a week) ( p = 0.022).
Most patients reported low physical activity and
none high-intensity exercise. BMI was 26.1 – 4.6 kg/m2
at baseline and did not significantly vary through-
out study. In total, 50% of the patients were overweight
and three out of the patients had grade 1 obesity (BMI
>30 kg/m2).
Significant associations between parameters at base-
line are presented in Tables 2 and 3. Interestingly, pica,
RLS, and ungual changes were related to age of men-
arche. In addition, associations between cognitive func-
tion measures and neurological symptoms, specifically
pica and reaction time in 2-back test, were observed.
Outcome after iron therapy
Thirty-four out of 35 patients showed response to oral
iron treatment, 24 showed complete response (16 at




Body mass index 26.1 4.6
Energy intake (kcal/day) 2194 415
Dietary iron intake (mg/day) 16.5 5.7
Hemoglobin (g/dL) 9.99 0.97
Hematocrit (%) 31.14 2.46




Red blood cell distribution width (%) 17.51 1.80
Serum ferritin (ng/mL) 4.23 1.96
Transferrin (mg/dL) 381.1 46.9
Serum iron (lg/dL) 24.83 7.87
PTH (pg/mL) 39.29 14.12
Median IQR
Age at menarche (years) 13 3
Menstrual cycle length (days) 28 5
Period length (days) 5 3
Heavy bleeding (days) 2 1
Values of the women who completed the study (n = 35).
IQR, interquartile range; PTH, parathyroid hormone; SD, standard
deviation.
Table 2. Univariate and Multivariate Logistic Regression Analyses of Several Clinical and Biochemical
Variables Associated with Nonhematological Symptomatology at Baseline
Symptom Variables
Univariate Multivariate
OR (95% CI) p OR (95% CI) p
Pica Menarche age 1.84 (1.05–3.22) 0.034 — —
Reaction time (2-back) 1.6 (1.06–2.45) 0.027 2.14 (1.19–3.87) 0.012
RLS Menarche age 0.57 (0.32–0.99) 0.045 — —
Serum total protein 0.07 (0.005–0.82) 0.035 0.08 (0.06–0.92) 0.043
Platelet count 1.03 (1.03–1.04) 0.023 — —
Cheilitis Mean corpuscular volume 0.64 (0.46–0.9) 0.01 — —
Mean corpuscular hemoglobin 0.37 (0.18–0.78) 0.008 0.388 (0.189–0.799) 0.01
Mean corpuscular hemoglobin concentration 0.26 (0.09–0.79) 0.017 — —
Red blood cell distribution width 1.79 (1.02–3.13) 0.041 — —
Serum iron 0.7 (0.52–0.96) 0.027 — —
Soluble transferrin receptor 1.35 (1.02–1.78) 0.038 — —
Transferrin saturation 0.28 (0.08–0.9) 0.033 — —
Serum folate 0.51 (0.28–0.95) 0.034 — —
Diffuse hair loss Procollagen type 1N-terminal propeptide 1.06 (1.01–1.13) 0.045 NA —
Ungual changes Menarche age 0.62 (0.39–0.9) 0.045 NA
CI, confidence interval; RLS, restless leg syndrome; NA, nonapplicable; OR, odds ratio.
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8 weeks and 8 at 16 weeks follow-up), and 10 showed
incomplete response. The patient who did not respond
to therapy (refractoriness) was excluded from the
study. This patient was further diagnosed with Helico-
bacter pylori infection.
Nineteen patients (54.3%) notified side effects
that were gastrointestinal symptoms including nau-
sea, constipation, loose stools, and epigastric pain.
Reported side effects were all mild, transient, and
self-limited and did not require discontinuation of
treatment.
All cases of pica, cheilitis, and RLS completely re-
solved with iron therapy, even when some patients did
not achieve complete response to treatment. Ungual
changes and hair loss improved in 92.3% and 84.2%
of women, respectively, but were not totally resolved.
Fatigue, headache, tinnitus, and dysphagia disappeared
after treatment. The clinical data and response to iron
treatment are summarized in Table 4.
Regarding cognitive function assessment, a better
performance in executive attention and working mem-
ory was observed after iron therapy, measured by
Flanker and 2-back tests, as is shown in Table 5. In
the Flanker task, an improvement of the IES was seen
in compatible and incompatible trials, and in the 2-
back task, a decrease in response latencies and an in-
crease in accuracy were observed.
Different patterns of associations among cognitive
function measures and biochemical and clinical data
were observed after treatment. The only correlations
that remained statistically significant were between
IES for incompatible trials (Flanker task) and BMI
(r = 0.42, p = 0.020), and between correct responses
and omission errors (2-back test) and BMI (r = 0.43,
p = 0.016; r = 0.43, p = 0.015). In addition, increase in
ferritin levels and reticulocyte count was associated
with a reduction in omission errors (r =0.40, p =
0.034; r =0.49, p = 0.026) and an increment in correct
responses (r = 0.42, p = 0.027; r = 0.50, p = 0.026).
Changes in biochemical parameters after iron treat-
ment included significant increases in serum folate,
vitamin B12, glucose, uric acid, total cholesterol, high-
density lipoprotein cholesterol, and bilirubin. Urea
decreased significantly. These results have been dis-
cussed elsewhere.23
Table 3. Associations Between Cognitive Function Measures and Other Parameters at Baseline
Test Variable Correlations Multiple regression analysis b coefficient (SE), p
Flanker task Inverse efficiency score
for compatible trials
PTH: r = 0.43, p = 0.015
Serum albumin level: r =0.47, p = 0.019
Reticulocyte count: r =0.44, p = 0.019
Fasting glucose: r = 0.41, p = 0.025
PTH b: 0.36 (1.4), p = 0.035
Fasting glucose b: 0.57 (3.5), p = 0.002
(R2 = 0.63, p < 0.001)
Inverse efficiency score
for incompatible trials
PTH: r = 0.4, p = 0.041
Serum iron levels: r =0.42, p = 0.016
PTH b: 0.52 (1.4), p = 0.003
(R2 = 0.52, p = 0.003)
2-Back test Reaction time Transferrin saturation: r =0.37, p = 0.041
Fasting glucose: r = 0.42, p = 0.025
No variables were entered into the equation
Correct responses BMI: r =0.37, p = 0.043
Transferrin saturation: r = 0.4, p = 0.027
Serum iron levels: r = 0.43, p = 0.018
Serum iron levels b: 0.44 (0.45), p = 0.01
BMI b: 0.37 (0.93), p = 0.029
(R2 = 0.32, p = 0.006)
Omission errors BMI: r = 0.37, p = 0.043
Serum protein level: r =0.45, p = 0.025
Serum albumin level: r =0.42, p = 0.047
Fasting glucose: r = 0.4, p = 0.03
Transferrin saturation: r =0.34, p = 0.027
Serum iron levels: r =0.43, p = 0.018
Serum iron levels b: 0.4 (0.39), p = 0.018
BMI b: 0.37 (0.8), p = 0.037
Fasting glucose b: 0.49 (0.58), p = 0.007
(R2 = 0.54, p < 0.001)
Commission errors Significant correlations not found
BMI, body mass index; SE, standard error.
Table 4. Characteristics of Nonhematological Symptoms
in Patients with Iron Deficiency Anemia and Response
to Therapy
Nonhematological symptoms Patients (%) Oral iron response (%)
Cheilitis 20.6 100
Pica 32.4 100
Restless leg syndrome 20.6 100
Hair loss 55.9 84.2
Ungual changes 38.2 92.3
Headache 11.7 100
Others 5.8 100










This research has focused on emphasizing the impor-
tance of the nonhematological manifestations of
IDA in women of reproductive age and on identifying
factors associated with this condition. Although sev-
eral published studies have concentrated on one spe-
cific aspect such as pica and cognitive function
impairment, we have tried to analyze all the data
taken as a whole.
Concerning medical history, we found that more
than half of our patients reported family history of
IDA, which is consistent with studies suggesting that
susceptibility to ID is, in part, influenced by genetics.
Genetic variants of iron genes, especially TMPRSS6,
HFE, transferrin, and hepcidin, may predispose indi-
viduals to IDA or protect them from it.16,18,24,25 In
contrast, a personal history of IDA was present in al-
most three quarters of the patients. These findings
support the convenience of screening for IDA in
those with either prior personal or family histories
of IDA.
As regards etiology, among women of reproductive
age, menstrual blood loss is the most common cause
of ID and IDA. Women with heavy menstrual bleeding
are at a higher risk.15,18,26 In line with these data,
68.6% of the patients in our study reported heavy
menstrual bleeding and few women used oral contra-
ceptives that are known to regulate menstruation.
Regarding the different factors for IDA, high menstrual
blood losses and no use of oral contraceptives, but not
dietary iron intake, have been consistently associated
with poor iron status in women,15,18,27,28 emphasizing
the importance of recognition and diagnosis of ID in
this particularly vulnerable female population.
Most of our patients (85.3%) reported nonhemato-
logical symptoms, highlighting its high incidence and
the fact that this symptomatology is often overlooked
if patients are not directly questioned about it. Diffuse
hair loss was the most prevalent symptom we observed
(55.9% of patients) followed by brittle nails (38.2%). In
the literature, both signs have been associated with
chronic ID and could at least partly arise from alter-
ation in epithelial cellular replication produced by
ID.2 Telogen effluvium, or the rapid shift of hair
from anagen (growing period) to telogen (resting peri-
od) phase, has been described as the mechanism under-
lying hair loss in women with ID.29 The most typical
lesion seen in nails associated with ID is koilonychia,
defined as a concavity of the outer surface of the nail
but it seems that this finding is now encountered rarely,
possible due to earlier detection of ID. Thinning and
flattening of the nail, as well as brittle nails, precede
the development of koilonychia.30 The fact that our pa-
tients reported improvement but not complete resolu-
tion of hair loss or brittle nails after iron administration
could indicate that there are other factors involved or
that a longer follow-up is necessary. In line with this,
it has been reported that, even with therapy, koilony-
chia takes a long period of time to return to a normal
appearance.30 Regarding hair loss, most authors recom-
mend maintaining serum ferritin at levels >40 ng/mL,29
which would need longer to be achieved. Another ID-
related alteration of epithelium, angular cheilitis, char-
acterized by ulcerations or fissures at the corners of the
mouth, was observed in 20.6% of patients and com-
pletely resolved with iron treatment. Angular stomatitis
is not specific of ID and can also been seen in other
nutritional deficiencies. It has been reported that IDA
predisposes to angular cheilitis and the lesions healed
with iron supplementation.31
IDA and ID also have a well-known association with
intense fatigue,32 which was present in almost a quarter
of the patients in our study. All cases reversed with iron
therapy. It could be argued that anemia could be re-
sponsible for fatigue, but it has been observed in non-
anemic individuals with ID in several reports. A recent
meta-analysis of studies in iron-deficient non-anemic
patients found that iron therapy improved objective
Table 5. Changes in Cognitive Function Measures after Iron Therapy
Test Variable Baseline (mean – SD) End of treatment (mean – SD)
Paired t-test
t p
Flanker task Inverse efficiency score for compatible trials (ms) 301.9 – 132.5 233.5 – 37.7 3.2 0.004
Inverse efficiency score for incompatible trials (ms) 312.2 – 131 253.6 – 41.4 2.6 0.014
2-Back test Reaction time (ms) 1333 – 2.2 1332.4 – 1.8 2.9 0.008
Correct responses (%) 57.9 – 22.5 68 – 21.6 2.3 0.029
Omission errors (%) 42.1 – 22.5 32 – 21.6 2.3 0.029
Commission errors (%) 15.9 – 14.6 15 – 14.2 0.3 ns
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and self-rated assessments of fatigue,33 reinforcing the
fact that ID is a broader condition with extensive health
consequences in addition to the well-known feature of
anemia. These data highlight that for women of child-
bearing age with unexplained prolonged fatigue, ID
should be considered.
Iron is also recognized to play a crucial role in main-
tenance of neuronal activity and networks.2 Linked to
this function, two neurological symptoms, pica and
RLS, have been associated with ID. Pica was reported
by 32.4% of our patients, consistent with the preva-
lence observed in other studies.34 Careful inquiry was
necessary because some patients were ashamed of
their behavior or underrated its importance. Various
forms of pica have been associated with ID, pagophagia
(pica for ice) being considered quite specific.35 In our
study, patients reported either pagophagia or food
pica, a subtype of pica that consists of compulsively eat-
ing one particular food, especially if crunchy.36 Exact
pathophysiology of pica in association with ID is
unknown but it is probably attributable to ID in the
central nervous system. The reasons why some patients
with ID manifest pica and others do not have yet to be
satisfactorily explained, but heritable traits could con-
tribute to pica susceptibility in adults with ID. All
cases of pica in this study resolved rapidly with iron
therapy even before any increase was noted in the he-
moglobin concentration, in agreement with previous
reports.34
RLS is a common disorder that manifests as an in-
tense urge to move the legs that is uncomfortable and
interferes with sleep. Although the exact pathophysiol-
ogy remains unclear, brain ID and altered dopaminer-
gic function appear to play an important role in the
pathogenesis of this condition.37 In our patients, the
prevalence of clinically significant RLS was 20.6%,
higher than that seen in the general population (5%–
15%),38 and all cases resolved with iron administration.
Despite its significant sleep morbidity, RLS with IDA is
often overlooked. In addition, we found that patients
with RLS showed lower serum protein level than the
rest of IDA women, which is according to a recent
study reporting lower serum albumin levels in RLS
patients than in a control group.39
A considerable body of evidence has established that
appropriate levels of brain iron are necessary for opti-
mal brain development and functioning.40 Nonethe-
less, despite the high prevalence of ID in women of
reproductive age, relatively few studies41–45 have exam-
ined the relationship between iron status and cognition
in this group, focusing instead on infants and children.
Our study found a correlation between iron serum
level and working memory measured by 2-back task
at baseline. After iron treatment, we detected an im-
provement in attention and working memory tests
measured by Flanker and 2-back tasks, corroborating
others’ previous findings that show that cognitive al-
terations are responsive to iron administration.46–48
Of note, there was a significant decrease in omission
but not commission errors in 2-back. This is in line
with studies reporting that these two types of errors
have different correlates and, thus, may represent dif-
ferent processes.49
In addition to correlations related to iron metabo-
lism, we observed an intriguing association between
parathyroid hormone (PTH) levels and IES (in com-
patible as well as in incompatible trials) in Flanker
task at baseline. This finding could be related to the
link between higher serum PTH levels and increased
odds of poor cognition suggested by some reports, al-
though it is not yet well established.50 Despite the
fact our study initially seemed to corroborate this pos-
sible link, the association between PTH levels and
Flanker test was not significant after iron therapy.
One possible explanation could be that IDA patients
presented higher PTH levels at the beginning of the
trial. Linked to this, higher levels of PTH have been
reported in patients with low hemoglobin and low fer-
ritin.51 Nevertheless, we could not detect statistically
significant differences in PTH levels before and after
therapy, although the small size of our sample limits
the results of our study. We also found an association
between BMI and accuracy in 2-back task both at the
baseline and after treatment, which agrees with the im-
paired working memory performance reported in over-
weight and obese young adults compared with healthy
weight controls.52
Conclusions
Despite the high prevalence of ID and IDA among
women, there is insufficient awareness of its unfavor-
able consequences beyond anemia. Iron plays an inte-
gral role in a wide range of physiological functions;
therefore, the health consequences of ID and IDA are
extensive and affect all aspects of the physical health
and well-being of women.
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